SMITH JASON DREW (General Counsel) sold 22.8% of their position (3.61K shares) of UROGEN PHARMA LTD. on the open market
Open‑market sale worth $26.0K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 9/2/2022ACC: 0001437749-22-021776
Officer· General Counsel
Since Aug 2020
-3.61K
Net shares
Net seller
$26.0K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
8.33K acquired · 11.94K disposed
Non-Derivative Transactions2
Ordinary Shares
Direct
Shares
+8.33K
Price / share
—
Trade value
—
% of position
111.9%
8/31/2022
7.45K→15.78K
Ordinary Shares
Direct
Shares
−3.61K
Price / share
$7.21
Trade value
$26K
% of position
22.8%
8/31/2022
15.78K→12.18K
Total
Net shares
+4.73K
Net value
-$26K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares Direct | 8/31/2022 | M · Option Exercise | +8.33K | — | — | 111.9% | 7.45K | 15.78K |
| Ordinary Shares Direct | 8/31/2022 | S · Sale | −3.61K | $7.21 | $26K | 22.8% | 15.78K | 12.18K |
| Total | +4.73K | -$26K | ||||||
Derivative Transactions1
Restricted Stock Units
Direct
Converts to
Ordinary Shares
8.33K shares
Shares
−8.33K
Strike price
Held after
8.33K
Exercisable
—
8/31/2022
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Restricted Stock Units Direct | Ordinary Shares8.33K shares | 8/31/2022 | M · Option Exercise | −8.33K | — | 8.33K |